Upholding the Principles of Autonomy, Beneficence, and Justice in Phase I Clinical Trials

Por Owonikoko, Taofeek K.
Publicado em 2013

Immune checkpoint inhibitors in small cell lung cancer

Por Pakkala, Suchita, Owonikoko, Taofeek K.
Publicado no J Thorac Dis (2018)

Immunotherapy of lung cancer

Por Owonikoko, Taofeek K., Borghaei, Hossein
Publicado no J Thorac Dis (2018)

Targeting the PI3K/AKT/mTOR Pathway: Biomarkers of Success and Tribulation

Por Owonikoko, Taofeek K., Khuri, Fadlo R.
Publicado em 2013

Small Cell Lung Cancer: Therapies and Targets

Por Pillai, Rathi N, Owonikoko, Taofeek K
Publicado em 2013

Biomarkers and Targeted Systemic Therapies in Advanced Non-Small Cell Lung Cancer

Por Kumar, Mukesh, Vinicius, Ernani, Owonikoko, Taofeek K.
Publicado no Mol Aspects Med (2015)

Taxanes: vesicants, irritants, or just irritating?

Por Barbee, Meagan S., Owonikoko, Taofeek K., Harvey, R. Donald
Publicado em 2014

Altered glutamine metabolism and therapeutic opportunities for lung cancer

Por Mohammed, Mohammed A., Deng, Xingming, Khuri, Fadlo R., Owonikoko, Taofeek K.
Publicado em 2013

Oncogenic role of EAPII in lung cancer development and its activation of the MAPK–ERK pathway

Por Li, C, Fan, S, Owonikoko, T K, Khuri, F R, Sun, S-Y, Li, R
Publicado em 2011

What is the role of maintenance therapy in the treatment of non-small cell lung cancer?

Por Jiang, Yixing, Owonikoko, Taofeek K., Ramalingam, Suresh S., Khuri, Fadlo R., Belani, Chandra P.
Publicado em 2010

Interactive Software “Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS©TM)” for Cancer Phase I Clinical Trials

Por Chen, Zhengjia, Wang, Zhibo, Wang, Haibin, Owonikoko, Taofeek K, Kowalski, Jeanne, Khuri, Fadlo R
Publicado em 2013

Vorinostat increases carboplatin and paclitaxel activity in non-small cell lung cancer cells

Por Owonikoko, Taofeek K., Ramalingam, Suresh S., Kanterewicz, Beatriz, Balius, Trent, Belani, Chandra P., Hershberger, Pamela A.
Publicado em 2010

Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells

Por Yao, Weilong, Yue, Ping, Zhang, Guojing, Owonikoko, Taofeek K., Khuri, Fadlo R., Sun, Shi-Yong
Publicado no Cancer Lett (2015)

GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth

Por Koo, Junghui, Wang, Xuerong, Owonikoko, Taofeek K., Ramalingam, Suresh S., Khuri, Fadlo R., Sun, Shi-Yong
Publicado no Oncotarget (2015)

Analysis of liver-directed therapies in U.S. cancer patients

Por Alese, O.B., Kim, S., Chen, Z., Ramalingam, S.S., Owonikoko, T.K., El-Rayes, B.F.
Publicado no Curr Oncol (2015)

A Bystander Effect of Lung Cancer Chemotherapy on Chronic Echinococcal Disease

Por Bangaru, Saroja D., Kozarsky, Phyllis E., Lee, Daniel J., Sica, Gabriel L., Owonikoko, Taofeek K.
Publicado no World J Oncol (2015)

Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing

Por Oh, You-Take, Deng, Jiusheng, Yue, Ping, Owonikoko, Taofeek K., Khuri, Fadlo R., Sun, Shi-Yong
Publicado no Oncogene (2015)

A systematic analysis of efficacy of second line chemotherapy in sensitive and refractory small cell lung cancer

Por Owonikoko, Taofeek K., Behera, Madhusmita, Chen, Zhengjia, Bhimani, Chandar, Curran, Walter J., Khuri, Fadlo R., Ramalingam, Suresh S.
Publicado em 2012

The Combination of RAD001 and NVP-BEZ235 Exerts Synergistic Anticancer Activity against Non-Small Cell Lung Cancer In Vitro and In Vivo

Por Xu, Cheng-Xiong, Li, Yikun, Yue, Ping, Owonikoko, Taofeek K., Ramalingam, Suresh S., Khuri, Fadlo R., Sun, Shi-Yong
Publicado em 2011

NNK promotes migration and invasion of lung cancer cells through activation of c-Src/PKCι/FAK loop

Por Shen, Jie, Xu, Lijun, Owonikoko, Taofeek K., Sun, Shi-Yong, Khuri, Fadlo R., Curran, Walter J., Deng, Xingming
Publicado em 2011